Skip to main content


Log in

Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin

  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript


Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over two decades. Since the early 1980s, the therapeutic efficacy of IVIg has been established in idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, dermatomyositis and Kawasaki syndrome, and the prevention of graft versus host disease in recipients of allogeneic bone marrow transplants. Its use has also been reported in a large number of other autoimmune and systemic inflammatory conditions. In this review, we discuss the mechanisms by which IVIg exerts immunomodulatory effects in immune pathologies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations


Corresponding author

Correspondence to M. D Kazatchkine.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ephrem, A., Misra, N., Hassan, G. et al. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin. Exper.Med. 5, 135–140 (2005).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

Key words